Japan’s ‘anticancer-CNS’ vs Korea’s ‘anticancer-antidiabetic’

The current environment of the Korean pharmaceutical industry is evaluated as similar to the Japanese 1990s in many aspects, such as the amount of sales, the R&D development steps and the government’s drug pricing policy.

However, the biggest difference is their focus in regards to senile disease; while Japan concentrated on anticancers and central nervous system(CNS) treatments, Korea is cur...